 | • レポートコード：MRC2-11QY11192 • 出版社/出版日：QYResearch / 2020年11月25日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、125ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：ヘルスケア |
| Single User | ￥585,000 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥877,500 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,170,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は乳癌モノクローナル抗体のグローバル市場について調査・分析したレポートです。種類別（ネイキッドMAb、コンジュゲートMAb）市場規模、用途別（病院、小売薬局、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別乳癌モノクローナル抗体の競争状況、市場シェア ・世界の乳癌モノクローナル抗体市場：種類別市場規模 2015年-2020年（ネイキッドMAb、コンジュゲートMAb） ・世界の乳癌モノクローナル抗体市場：種類別市場規模予測 2021年-2026年（ネイキッドMAb、コンジュゲートMAb） ・世界の乳癌モノクローナル抗体市場：用途別市場規模 2015年-2020年（病院、小売薬局、その他） ・世界の乳癌モノクローナル抗体市場：用途別市場規模予測 2021年-2026年（病院、小売薬局、その他） ・北米の乳癌モノクローナル抗体市場分析：米国、カナダ ・ヨーロッパの乳癌モノクローナル抗体市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの乳癌モノクローナル抗体市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の乳癌モノクローナル抗体市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの乳癌モノクローナル抗体市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Amgen、Roche、Mylan、Array BioPharma、Biocad、Boehringer Ingelheim、Bristol-Myers Squibb、Celldex Therapeutics、Celltrion、Daiichi Sankyo、GlaxoSmithKline、Immunomedics、MacroGenics、Merck、Novartis、Oncothyreon、Pfizer、Puma Biotechnology、Seattle Genetics、Sun Pharmaceutical Industries、Synta Pharmaceuticals、Teva Pharmaceuticals ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Breast cancer is characterized by the malignancy of cells in the tissues of the breast. HER-2 breast cancer is the most common type of breast cancer. The HER-2 protein, present on the surface of normal breast cells, affects the growth of the malignant cells. The uncontrolled synthesis of this protein stimulates the growth and division of malignant cells.
The breast cancer monoclonal antibodies (mAbs) market is one of the fastest-growing segments of the global mAbs market and has gained major research significance among biotech and pharmaceutical companies due to the presence of high unmet needs in this area. Antibodies are increasingly becoming the best choice to treat cancers, including breast cancer. The use of antibody-drug conjugates (ADCs),including radioimmunotherapy and antibody-directed enzyme prodrug therapy, is increasing rapidly. ADCs are highly effective cytotoxic drugs linked to mAbs. These drugs have shown to be potent and efficient in treating breast cancer. This has propelled vendors to focus on novel technologies such as Seattle Genetics (SGEN), ImmunoGen (IMGN), and Immunomedics (IMMU). The rising use of these antibodies in drug development increases revenue generation in the breast cancer mAbs market, contributing to market growth.
Market Analysis and Insights: Global Breast Cancer Monoclonal Antibodies Market
The global Breast Cancer Monoclonal Antibodies market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Breast Cancer Monoclonal Antibodies Scope and Market Size
Breast Cancer Monoclonal Antibodies market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Breast Cancer Monoclonal Antibodies market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The key players covered in this study
Amgen
Roche
Mylan
Array BioPharma
Biocad
Boehringer Ingelheim
Bristol-Myers Squibb
Celldex Therapeutics
Celltrion
Daiichi Sankyo
GlaxoSmithKline
Immunomedics
MacroGenics
Merck
Novartis
Oncothyreon
Pfizer
Puma Biotechnology
Seattle Genetics
Sun Pharmaceutical Industries
Synta Pharmaceuticals
Teva Pharmaceuticals
Market segment by Type, the product can be split into
Naked MAbs
Conjugated MAbs
Market segment by Application, split into
Hospitals
Retail Pharmacies
Others
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Breast Cancer Monoclonal Antibodies Revenue
1.4 Market by Type
1.4.1 Global Breast Cancer Monoclonal Antibodies Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Naked MAbs
1.4.3 Conjugated MAbs
1.5 Market by Application
1.5.1 Global Breast Cancer Monoclonal Antibodies Market Share by Application: 2020 VS 2026
1.5.2 Hospitals
1.5.3 Retail Pharmacies
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Breast Cancer Monoclonal Antibodies Market Perspective (2015-2026)
2.2 Global Breast Cancer Monoclonal Antibodies Growth Trends by Regions
2.2.1 Breast Cancer Monoclonal Antibodies Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Breast Cancer Monoclonal Antibodies Historic Market Share by Regions (2015-2020)
2.2.3 Breast Cancer Monoclonal Antibodies Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Breast Cancer Monoclonal Antibodies Market Growth Strategy
2.3.6 Primary Interviews with Key Breast Cancer Monoclonal Antibodies Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Breast Cancer Monoclonal Antibodies Players by Market Size
3.1.1 Global Top Breast Cancer Monoclonal Antibodies Players by Revenue (2015-2020)
3.1.2 Global Breast Cancer Monoclonal Antibodies Revenue Market Share by Players (2015-2020)
3.1.3 Global Breast Cancer Monoclonal Antibodies Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Breast Cancer Monoclonal Antibodies Market Concentration Ratio
3.2.1 Global Breast Cancer Monoclonal Antibodies Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Breast Cancer Monoclonal Antibodies Revenue in 2019
3.3 Breast Cancer Monoclonal Antibodies Key Players Head office and Area Served
3.4 Key Players Breast Cancer Monoclonal Antibodies Product Solution and Service
3.5 Date of Enter into Breast Cancer Monoclonal Antibodies Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Breast Cancer Monoclonal Antibodies Historic Market Size by Type (2015-2020)
4.2 Global Breast Cancer Monoclonal Antibodies Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Breast Cancer Monoclonal Antibodies Market Size by Application (2015-2020)
5.2 Global Breast Cancer Monoclonal Antibodies Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Breast Cancer Monoclonal Antibodies Market Size (2015-2020)
6.2 Breast Cancer Monoclonal Antibodies Key Players in North America (2019-2020)
6.3 North America Breast Cancer Monoclonal Antibodies Market Size by Type (2015-2020)
6.4 North America Breast Cancer Monoclonal Antibodies Market Size by Application (2015-2020)
7 Europe
7.1 Europe Breast Cancer Monoclonal Antibodies Market Size (2015-2020)
7.2 Breast Cancer Monoclonal Antibodies Key Players in Europe (2019-2020)
7.3 Europe Breast Cancer Monoclonal Antibodies Market Size by Type (2015-2020)
7.4 Europe Breast Cancer Monoclonal Antibodies Market Size by Application (2015-2020)
8 China
8.1 China Breast Cancer Monoclonal Antibodies Market Size (2015-2020)
8.2 Breast Cancer Monoclonal Antibodies Key Players in China (2019-2020)
8.3 China Breast Cancer Monoclonal Antibodies Market Size by Type (2015-2020)
8.4 China Breast Cancer Monoclonal Antibodies Market Size by Application (2015-2020)
9 Japan
9.1 Japan Breast Cancer Monoclonal Antibodies Market Size (2015-2020)
9.2 Breast Cancer Monoclonal Antibodies Key Players in Japan (2019-2020)
9.3 Japan Breast Cancer Monoclonal Antibodies Market Size by Type (2015-2020)
9.4 Japan Breast Cancer Monoclonal Antibodies Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Breast Cancer Monoclonal Antibodies Market Size (2015-2020)
10.2 Breast Cancer Monoclonal Antibodies Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Breast Cancer Monoclonal Antibodies Market Size by Type (2015-2020)
10.4 Southeast Asia Breast Cancer Monoclonal Antibodies Market Size by Application (2015-2020)
11 India
11.1 India Breast Cancer Monoclonal Antibodies Market Size (2015-2020)
11.2 Breast Cancer Monoclonal Antibodies Key Players in India (2019-2020)
11.3 India Breast Cancer Monoclonal Antibodies Market Size by Type (2015-2020)
11.4 India Breast Cancer Monoclonal Antibodies Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Breast Cancer Monoclonal Antibodies Market Size (2015-2020)
12.2 Breast Cancer Monoclonal Antibodies Key Players in Central & South America (2019-2020)
12.3 Central & South America Breast Cancer Monoclonal Antibodies Market Size by Type (2015-2020)
12.4 Central & South America Breast Cancer Monoclonal Antibodies Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 Amgen
13.1.1 Amgen Company Details
13.1.2 Amgen Business Overview
13.1.3 Amgen Breast Cancer Monoclonal Antibodies Introduction
13.1.4 Amgen Revenue in Breast Cancer Monoclonal Antibodies Business (2015-2020))
13.1.5 Amgen Recent Development
13.2 Roche
13.2.1 Roche Company Details
13.2.2 Roche Business Overview
13.2.3 Roche Breast Cancer Monoclonal Antibodies Introduction
13.2.4 Roche Revenue in Breast Cancer Monoclonal Antibodies Business (2015-2020)
13.2.5 Roche Recent Development
13.3 Mylan
13.3.1 Mylan Company Details
13.3.2 Mylan Business Overview
13.3.3 Mylan Breast Cancer Monoclonal Antibodies Introduction
13.3.4 Mylan Revenue in Breast Cancer Monoclonal Antibodies Business (2015-2020)
13.3.5 Mylan Recent Development
13.4 Array BioPharma
13.4.1 Array BioPharma Company Details
13.4.2 Array BioPharma Business Overview
13.4.3 Array BioPharma Breast Cancer Monoclonal Antibodies Introduction
13.4.4 Array BioPharma Revenue in Breast Cancer Monoclonal Antibodies Business (2015-2020)
13.4.5 Array BioPharma Recent Development
13.5 Biocad
13.5.1 Biocad Company Details
13.5.2 Biocad Business Overview
13.5.3 Biocad Breast Cancer Monoclonal Antibodies Introduction
13.5.4 Biocad Revenue in Breast Cancer Monoclonal Antibodies Business (2015-2020)
13.5.5 Biocad Recent Development
13.6 Boehringer Ingelheim
13.6.1 Boehringer Ingelheim Company Details
13.6.2 Boehringer Ingelheim Business Overview
13.6.3 Boehringer Ingelheim Breast Cancer Monoclonal Antibodies Introduction
13.6.4 Boehringer Ingelheim Revenue in Breast Cancer Monoclonal Antibodies Business (2015-2020)
13.6.5 Boehringer Ingelheim Recent Development
13.7 Bristol-Myers Squibb
13.7.1 Bristol-Myers Squibb Company Details
13.7.2 Bristol-Myers Squibb Business Overview
13.7.3 Bristol-Myers Squibb Breast Cancer Monoclonal Antibodies Introduction
13.7.4 Bristol-Myers Squibb Revenue in Breast Cancer Monoclonal Antibodies Business (2015-2020)
13.7.5 Bristol-Myers Squibb Recent Development
13.8 Celldex Therapeutics
13.8.1 Celldex Therapeutics Company Details
13.8.2 Celldex Therapeutics Business Overview
13.8.3 Celldex Therapeutics Breast Cancer Monoclonal Antibodies Introduction
13.8.4 Celldex Therapeutics Revenue in Breast Cancer Monoclonal Antibodies Business (2015-2020)
13.8.5 Celldex Therapeutics Recent Development
13.9 Celltrion
13.9.1 Celltrion Company Details
13.9.2 Celltrion Business Overview
13.9.3 Celltrion Breast Cancer Monoclonal Antibodies Introduction
13.9.4 Celltrion Revenue in Breast Cancer Monoclonal Antibodies Business (2015-2020)
13.9.5 Celltrion Recent Development
13.10 Daiichi Sankyo
13.10.1 Daiichi Sankyo Company Details
13.10.2 Daiichi Sankyo Business Overview
13.10.3 Daiichi Sankyo Breast Cancer Monoclonal Antibodies Introduction
13.10.4 Daiichi Sankyo Revenue in Breast Cancer Monoclonal Antibodies Business (2015-2020)
13.10.5 Daiichi Sankyo Recent Development
13.11 GlaxoSmithKline
10.11.1 GlaxoSmithKline Company Details
10.11.2 GlaxoSmithKline Business Overview
10.11.3 GlaxoSmithKline Breast Cancer Monoclonal Antibodies Introduction
10.11.4 GlaxoSmithKline Revenue in Breast Cancer Monoclonal Antibodies Business (2015-2020)
10.11.5 GlaxoSmithKline Recent Development
13.12 Immunomedics
10.12.1 Immunomedics Company Details
10.12.2 Immunomedics Business Overview
10.12.3 Immunomedics Breast Cancer Monoclonal Antibodies Introduction
10.12.4 Immunomedics Revenue in Breast Cancer Monoclonal Antibodies Business (2015-2020)
10.12.5 Immunomedics Recent Development
13.13 MacroGenics
10.13.1 MacroGenics Company Details
10.13.2 MacroGenics Business Overview
10.13.3 MacroGenics Breast Cancer Monoclonal Antibodies Introduction
10.13.4 MacroGenics Revenue in Breast Cancer Monoclonal Antibodies Business (2015-2020)
10.13.5 MacroGenics Recent Development
13.14 Merck
10.14.1 Merck Company Details
10.14.2 Merck Business Overview
10.14.3 Merck Breast Cancer Monoclonal Antibodies Introduction
10.14.4 Merck Revenue in Breast Cancer Monoclonal Antibodies Business (2015-2020)
10.14.5 Merck Recent Development
13.15 Novartis
10.15.1 Novartis Company Details
10.15.2 Novartis Business Overview
10.15.3 Novartis Breast Cancer Monoclonal Antibodies Introduction
10.15.4 Novartis Revenue in Breast Cancer Monoclonal Antibodies Business (2015-2020)
10.15.5 Novartis Recent Development
13.16 Oncothyreon
10.16.1 Oncothyreon Company Details
10.16.2 Oncothyreon Business Overview
10.16.3 Oncothyreon Breast Cancer Monoclonal Antibodies Introduction
10.16.4 Oncothyreon Revenue in Breast Cancer Monoclonal Antibodies Business (2015-2020)
10.16.5 Oncothyreon Recent Development
13.17 Pfizer
10.17.1 Pfizer Company Details
10.17.2 Pfizer Business Overview
10.17.3 Pfizer Breast Cancer Monoclonal Antibodies Introduction
10.17.4 Pfizer Revenue in Breast Cancer Monoclonal Antibodies Business (2015-2020)
10.17.5 Pfizer Recent Development
13.18 Puma Biotechnology
10.18.1 Puma Biotechnology Company Details
10.18.2 Puma Biotechnology Business Overview
10.18.3 Puma Biotechnology Breast Cancer Monoclonal Antibodies Introduction
10.18.4 Puma Biotechnology Revenue in Breast Cancer Monoclonal Antibodies Business (2015-2020)
10.18.5 Puma Biotechnology Recent Development
13.19 Seattle Genetics
10.19.1 Seattle Genetics Company Details
10.19.2 Seattle Genetics Business Overview
10.19.3 Seattle Genetics Breast Cancer Monoclonal Antibodies Introduction
10.19.4 Seattle Genetics Revenue in Breast Cancer Monoclonal Antibodies Business (2015-2020)
10.19.5 Seattle Genetics Recent Development
13.20 Sun Pharmaceutical Industries
10.20.1 Sun Pharmaceutical Industries Company Details
10.20.2 Sun Pharmaceutical Industries Business Overview
10.20.3 Sun Pharmaceutical Industries Breast Cancer Monoclonal Antibodies Introduction
10.20.4 Sun Pharmaceutical Industries Revenue in Breast Cancer Monoclonal Antibodies Business (2015-2020)
10.20.5 Sun Pharmaceutical Industries Recent Development
13.21 Synta Pharmaceuticals
10.21.1 Synta Pharmaceuticals Company Details
10.21.2 Synta Pharmaceuticals Business Overview
10.21.3 Synta Pharmaceuticals Breast Cancer Monoclonal Antibodies Introduction
10.21.4 Synta Pharmaceuticals Revenue in Breast Cancer Monoclonal Antibodies Business (2015-2020)
10.21.5 Synta Pharmaceuticals Recent Development
13.22 Teva Pharmaceuticals
10.22.1 Teva Pharmaceuticals Company Details
10.22.2 Teva Pharmaceuticals Business Overview
10.22.3 Teva Pharmaceuticals Breast Cancer Monoclonal Antibodies Introduction
10.22.4 Teva Pharmaceuticals Revenue in Breast Cancer Monoclonal Antibodies Business (2015-2020)
10.22.5 Teva Pharmaceuticals Recent Development
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
Table 1. Breast Cancer Monoclonal Antibodies Key Market Segments
Table 2. Key Players Covered: Ranking by Breast Cancer Monoclonal Antibodies Revenue
Table 3. Ranking of Global Top Breast Cancer Monoclonal Antibodies Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Breast Cancer Monoclonal Antibodies Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Naked MAbs
Table 6. Key Players of Conjugated MAbs
Table 7. Global Breast Cancer Monoclonal Antibodies Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 8. Global Breast Cancer Monoclonal Antibodies Market Size by Regions (US$ Million): 2020 VS 2026
Table 9. Global Breast Cancer Monoclonal Antibodies Market Size by Regions (2015-2020) (US$ Million)
Table 10. Global Breast Cancer Monoclonal Antibodies Market Share by Regions (2015-2020)
Table 11. Global Breast Cancer Monoclonal Antibodies Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 12. Global Breast Cancer Monoclonal Antibodies Market Share by Regions (2021-2026)
Table 13. Market Top Trends
Table 14. Key Drivers: Impact Analysis
Table 15. Key Challenges
Table 16. Breast Cancer Monoclonal Antibodies Market Growth Strategy
Table 17. Main Points Interviewed from Key Breast Cancer Monoclonal Antibodies Players
Table 18. Global Breast Cancer Monoclonal Antibodies Revenue by Players (2015-2020) (Million US$)
Table 19. Global Breast Cancer Monoclonal Antibodies Market Share by Players (2015-2020)
Table 20. Global Top Breast Cancer Monoclonal Antibodies Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Breast Cancer Monoclonal Antibodies as of 2019)
Table 21. Global Breast Cancer Monoclonal Antibodies by Players Market Concentration Ratio (CR5 and HHI)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Breast Cancer Monoclonal Antibodies Product Solution and Service
Table 24. Date of Enter into Breast Cancer Monoclonal Antibodies Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Breast Cancer Monoclonal Antibodies Market Size by Type (2015-2020) (Million US$)
Table 27. Global Breast Cancer Monoclonal Antibodies Market Size Share by Type (2015-2020)
Table 28. Global Breast Cancer Monoclonal Antibodies Revenue Market Share by Type (2021-2026)
Table 29. Global Breast Cancer Monoclonal Antibodies Market Size Share by Application (2015-2020)
Table 30. Global Breast Cancer Monoclonal Antibodies Market Size by Application (2015-2020) (Million US$)
Table 31. Global Breast Cancer Monoclonal Antibodies Market Size Share by Application (2021-2026)
Table 32. North America Key Players Breast Cancer Monoclonal Antibodies Revenue (2019-2020) (Million US$)
Table 33. North America Key Players Breast Cancer Monoclonal Antibodies Market Share (2019-2020)
Table 34. North America Breast Cancer Monoclonal Antibodies Market Size by Type (2015-2020) (Million US$)
Table 35. North America Breast Cancer Monoclonal Antibodies Market Share by Type (2015-2020)
Table 36. North America Breast Cancer Monoclonal Antibodies Market Size by Application (2015-2020) (Million US$)
Table 37. North America Breast Cancer Monoclonal Antibodies Market Share by Application (2015-2020)
Table 38. Europe Key Players Breast Cancer Monoclonal Antibodies Revenue (2019-2020) (Million US$)
Table 39. Europe Key Players Breast Cancer Monoclonal Antibodies Market Share (2019-2020)
Table 40. Europe Breast Cancer Monoclonal Antibodies Market Size by Type (2015-2020) (Million US$)
Table 41. Europe Breast Cancer Monoclonal Antibodies Market Share by Type (2015-2020)
Table 42. Europe Breast Cancer Monoclonal Antibodies Market Size by Application (2015-2020) (Million US$)
Table 43. Europe Breast Cancer Monoclonal Antibodies Market Share by Application (2015-2020)
Table 44. China Key Players Breast Cancer Monoclonal Antibodies Revenue (2019-2020) (Million US$)
Table 45. China Key Players Breast Cancer Monoclonal Antibodies Market Share (2019-2020)
Table 46. China Breast Cancer Monoclonal Antibodies Market Size by Type (2015-2020) (Million US$)
Table 47. China Breast Cancer Monoclonal Antibodies Market Share by Type (2015-2020)
Table 48. China Breast Cancer Monoclonal Antibodies Market Size by Application (2015-2020) (Million US$)
Table 49. China Breast Cancer Monoclonal Antibodies Market Share by Application (2015-2020)
Table 50. Japan Key Players Breast Cancer Monoclonal Antibodies Revenue (2019-2020) (Million US$)
Table 51. Japan Key Players Breast Cancer Monoclonal Antibodies Market Share (2019-2020)
Table 52. Japan Breast Cancer Monoclonal Antibodies Market Size by Type (2015-2020) (Million US$)
Table 53. Japan Breast Cancer Monoclonal Antibodies Market Share by Type (2015-2020)
Table 54. Japan Breast Cancer Monoclonal Antibodies Market Size by Application (2015-2020) (Million US$)
Table 55. Japan Breast Cancer Monoclonal Antibodies Market Share by Application (2015-2020)
Table 56. Southeast Asia Key Players Breast Cancer Monoclonal Antibodies Revenue (2019-2020) (Million US$)
Table 57. Southeast Asia Key Players Breast Cancer Monoclonal Antibodies Market Share (2019-2020)
Table 58. Southeast Asia Breast Cancer Monoclonal Antibodies Market Size by Type (2015-2020) (Million US$)
Table 59. Southeast Asia Breast Cancer Monoclonal Antibodies Market Share by Type (2015-2020)
Table 60. Southeast Asia Breast Cancer Monoclonal Antibodies Market Size by Application (2015-2020) (Million US$)
Table 61. Southeast Asia Breast Cancer Monoclonal Antibodies Market Share by Application (2015-2020)
Table 62. India Key Players Breast Cancer Monoclonal Antibodies Revenue (2019-2020) (Million US$)
Table 63. India Key Players Breast Cancer Monoclonal Antibodies Market Share (2019-2020)
Table 64. India Breast Cancer Monoclonal Antibodies Market Size by Type (2015-2020) (Million US$)
Table 65. India Breast Cancer Monoclonal Antibodies Market Share by Type (2015-2020)
Table 66. India Breast Cancer Monoclonal Antibodies Market Size by Application (2015-2020) (Million US$)
Table 67. India Breast Cancer Monoclonal Antibodies Market Share by Application (2015-2020)
Table 68. Central & South America Key Players Breast Cancer Monoclonal Antibodies Revenue (2019-2020) (Million US$)
Table 69. Central & South America Key Players Breast Cancer Monoclonal Antibodies Market Share (2019-2020)
Table 70. Central & South America Breast Cancer Monoclonal Antibodies Market Size by Type (2015-2020) (Million US$)
Table 71. Central & South America Breast Cancer Monoclonal Antibodies Market Share by Type (2015-2020)
Table 72. Central & South America Breast Cancer Monoclonal Antibodies Market Size by Application (2015-2020) (Million US$)
Table 73. Central & South America Breast Cancer Monoclonal Antibodies Market Share by Application (2015-2020)
Table 74. Amgen Company Details
Table 75. Amgen Business Overview
Table 76. Amgen Product
Table 77. Amgen Revenue in Breast Cancer Monoclonal Antibodies Business (2015-2020) (Million US$)
Table 78. Amgen Recent Development
Table 79. Roche Company Details
Table 80. Roche Business Overview
Table 81. Roche Product
Table 82. Roche Revenue in Breast Cancer Monoclonal Antibodies Business (2015-2020) (Million US$)
Table 83. Roche Recent Development
Table 84. Mylan Company Details
Table 85. Mylan Business Overview
Table 86. Mylan Product
Table 87. Mylan Revenue in Breast Cancer Monoclonal Antibodies Business (2015-2020) (Million US$)
Table 88. Mylan Recent Development
Table 89. Array BioPharma Company Details
Table 90. Array BioPharma Business Overview
Table 91. Array BioPharma Product
Table 92. Array BioPharma Revenue in Breast Cancer Monoclonal Antibodies Business (2015-2020) (Million US$)
Table 93. Array BioPharma Recent Development
Table 94. Biocad Company Details
Table 95. Biocad Business Overview
Table 96. Biocad Product
Table 97. Biocad Revenue in Breast Cancer Monoclonal Antibodies Business (2015-2020) (Million US$)
Table 98. Biocad Recent Development
Table 99. Boehringer Ingelheim Company Details
Table 100. Boehringer Ingelheim Business Overview
Table 101. Boehringer Ingelheim Product
Table 102. Boehringer Ingelheim Revenue in Breast Cancer Monoclonal Antibodies Business (2015-2020) (Million US$)
Table 103. Boehringer Ingelheim Recent Development
Table 104. Bristol-Myers Squibb Company Details
Table 105. Bristol-Myers Squibb Business Overview
Table 106. Bristol-Myers Squibb Product
Table 107. Bristol-Myers Squibb Revenue in Breast Cancer Monoclonal Antibodies Business (2015-2020) (Million US$)
Table 108. Bristol-Myers Squibb Recent Development
Table 109. Celldex Therapeutics Business Overview
Table 110. Celldex Therapeutics Product
Table 111. Celldex Therapeutics Company Details
Table 112. Celldex Therapeutics Revenue in Breast Cancer Monoclonal Antibodies Business (2015-2020) (Million US$)
Table 113. Celldex Therapeutics Recent Development
Table 114. Celltrion Company Details
Table 115. Celltrion Business Overview
Table 116. Celltrion Product
Table 117. Celltrion Revenue in Breast Cancer Monoclonal Antibodies Business (2015-2020) (Million US$)
Table 118. Celltrion Recent Development
Table 119. Daiichi Sankyo Company Details
Table 120. Daiichi Sankyo Business Overview
Table 121. Daiichi Sankyo Product
Table 122. Daiichi Sankyo Revenue in Breast Cancer Monoclonal Antibodies Business (2015-2020) (Million US$)
Table 123. Daiichi Sankyo Recent Development
Table 124. GlaxoSmithKline Company Details
Table 125. GlaxoSmithKline Business Overview
Table 126. GlaxoSmithKline Product
Table 127. GlaxoSmithKline Revenue in Breast Cancer Monoclonal Antibodies Business (2015-2020) (Million US$)
Table 128. GlaxoSmithKline Recent Development
Table 129. Immunomedics Company Details
Table 130. Immunomedics Business Overview
Table 131. Immunomedics Product
Table 132. Immunomedics Revenue in Breast Cancer Monoclonal Antibodies Business (2015-2020) (Million US$)
Table 133. Immunomedics Recent Development
Table 134. MacroGenics Company Details
Table 135. MacroGenics Business Overview
Table 136. MacroGenics Product
Table 137. MacroGenics Revenue in Breast Cancer Monoclonal Antibodies Business (2015-2020) (Million US$)
Table 138. MacroGenics Recent Development
Table 139. Merck Company Details
Table 140. Merck Business Overview
Table 141. Merck Product
Table 142. Merck Revenue in Breast Cancer Monoclonal Antibodies Business (2015-2020) (Million US$)
Table 143. Merck Recent Development
Table 144. Novartis Company Details
Table 145. Novartis Business Overview
Table 146. Novartis Product
Table 147. Novartis Revenue in Breast Cancer Monoclonal Antibodies Business (2015-2020) (Million US$)
Table 148. Novartis Recent Development
Table 149. Oncothyreon Company Details
Table 150. Oncothyreon Business Overview
Table 151. Oncothyreon Product
Table 152. Oncothyreon Revenue in Breast Cancer Monoclonal Antibodies Business (2015-2020) (Million US$)
Table 153. Oncothyreon Recent Development
Table 154. Pfizer Company Details
Table 155. Pfizer Business Overview
Table 156. Pfizer Product
Table 157. Pfizer Revenue in Breast Cancer Monoclonal Antibodies Business (2015-2020) (Million US$)
Table 158. Pfizer Recent Development
Table 159. Puma Biotechnology Company Details
Table 160. Puma Biotechnology Business Overview
Table 161. Puma Biotechnology Product
Table 162. Puma Biotechnology Revenue in Breast Cancer Monoclonal Antibodies Business (2015-2020) (Million US$)
Table 163. Puma Biotechnology Recent Development
Table 164. Seattle Genetics Company Details
Table 165. Seattle Genetics Business Overview
Table 166. Seattle Genetics Product
Table 167. Seattle Genetics Revenue in Breast Cancer Monoclonal Antibodies Business (2015-2020) (Million US$)
Table 168. Seattle Genetics Recent Development
Table 169. Sun Pharmaceutical Industries Company Details
Table 170. Sun Pharmaceutical Industries Business Overview
Table 171. Sun Pharmaceutical Industries Product
Table 172. Sun Pharmaceutical Industries Revenue in Breast Cancer Monoclonal Antibodies Business (2015-2020) (Million US$)
Table 173. Sun Pharmaceutical Industries Recent Development
Table 174. Synta Pharmaceuticals Company Details
Table 175. Synta Pharmaceuticals Business Overview
Table 176. Synta Pharmaceuticals Product
Table 177. Synta Pharmaceuticals Revenue in Breast Cancer Monoclonal Antibodies Business (2015-2020) (Million US$)
Table 178. Synta Pharmaceuticals Recent Development
Table 179. Teva Pharmaceuticals Company Details
Table 180. Teva Pharmaceuticals Business Overview
Table 181. Teva Pharmaceuticals Product
Table 182. Teva Pharmaceuticals Revenue in Breast Cancer Monoclonal Antibodies Business (2015-2020) (Million US$)
Table 183. Teva Pharmaceuticals Recent Development
Table 184. Research Programs/Design for This Report
Table 185. Key Data Information from Secondary Sources
Table 186. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Breast Cancer Monoclonal Antibodies Market Share by Type: 2020 VS 2026
Figure 2. Naked MAbs Features
Figure 3. Conjugated MAbs Features
Figure 4. Global Breast Cancer Monoclonal Antibodies Market Share by Application: 2020 VS 2026
Figure 5. Hospitals Case Studies
Figure 6. Retail Pharmacies Case Studies
Figure 7. Others Case Studies
Figure 8. Breast Cancer Monoclonal Antibodies Report Years Considered
Figure 9. Global Breast Cancer Monoclonal Antibodies Market Size YoY Growth 2015-2026 (US$ Million)
Figure 10. Global Breast Cancer Monoclonal Antibodies Market Share by Regions: 2020 VS 2026
Figure 11. Global Breast Cancer Monoclonal Antibodies Market Share by Regions (2021-2026)
Figure 12. Porter's Five Forces Analysis
Figure 13. Global Breast Cancer Monoclonal Antibodies Market Share by Players in 2019
Figure 14. Global Top Breast Cancer Monoclonal Antibodies Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Breast Cancer Monoclonal Antibodies as of 2019
Figure 15. The Top 10 and 5 Players Market Share by Breast Cancer Monoclonal Antibodies Revenue in 2019
Figure 16. North America Breast Cancer Monoclonal Antibodies Market Size YoY Growth (2015-2020) (Million US$)
Figure 17. Europe Breast Cancer Monoclonal Antibodies Market Size YoY Growth (2015-2020) (Million US$)
Figure 18. China Breast Cancer Monoclonal Antibodies Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. Japan Breast Cancer Monoclonal Antibodies Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Southeast Asia Breast Cancer Monoclonal Antibodies Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. India Breast Cancer Monoclonal Antibodies Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Central & South America Breast Cancer Monoclonal Antibodies Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Bottom-up and Top-down Approaches for This Report
Figure 24. Data Triangulation
Figure 25. Key Executives Interviewed
モノクローナル抗体(mAb)バイオシミラーの世界市場（～2026年） A biosimilar medicine is a medicinal product of biological origin that is produced in a living organism following a procedure equivalent to a biological drug and adhering to the same quality criteria, hence the name biosimilars. In short, they are biological drugs that are “equivalent” in terms of q…- 癌治療用モノクローナル抗体の世界市場（～2026年） The mAbs, which are produced by genetic engineering, target antigens in cells, tissues, and organs. They are used in clinical applications to treat diseases with excellent efficacy and minimal side effects. Their MOA, absence of generic pathway, and therapeutic applications distinguish them from oth…
- トリプルネガティブ乳がん治療の世界市場（～2026年） Market Analysis and Insights: Global Triple-Negative Breast Cancer Treatment Market The global Triple-Negative Breast Cancer Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Triple-Negative Breast Cancer Treat…
- 乳癌治療の世界市場（～2026年） Market Analysis and Insights: Global Breast Cancer Therapeutic Market The global Breast Cancer Therapeutic market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Breast Cancer Therapeutic Scope and Market Size Breast Cancer T…
- HER2陰性乳がん治療の世界市場（～2026年） HER2 (human epidermal growth factor receptor 2) is a protein that appears on the surface of some breast cancer cells. It may also be called HER2/neu or ErbB2.HER2-negative breast cancer means that the people have little or no HER2 protein. Market Analysis and Insights: Global HER2-negative breast ca…